At the news
? NEUTRALIMPACT 3/10 144 filed Aug 26, 2026 at 16:43 ET
Director Jeffrey Kindler filed a Form 144 to sell 185,000 shares of Precigen (PGEN) at an estimated aggregate value of $1,372,700. The shares were acquired through restricted stock unit vestings from 2023 to 2026. While the sale is modest relative to the company's $2.6B market cap, it comes amid a period of heavy institutional accumulation and a 78% bullish analyst consensus, making the timing notable but not alarming for a director-level diversification trade.
- Director Jeffrey Kindler filed Form 144 to sell 185,000 shares of Precigen (PGEN).
- Estimated aggregate sale value is $1,372,700.
- Shares were acquired via restricted stock unit vestings on 03/09/2023, 03/09/2024, 03/13/2025, 03/13/2026, and 03/10/2026.
- The sale is being executed through Goldman Sachs & Co. LLC.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access